Ying Liu

Ying Liu

Auto-generated profile, based on publicly available information

Ying Liu

New York Medical College

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2023 in Allergy
Verified
Journal Article
Closed access
EDEster Del Duca
Ester Del Duca
HHHelen He
Helen He
YLYing Liu
Ying Liu
APAngel D. Pagan
Angel D. Pagan
EDEden David
Eden David
EGEmma Guttman‐Yassky
Emma Guttman‐Yassky


8 August 2024 in Allergy
Verified
Journal Article
Closed access
MKMadeline Kim
Madeline Kim
EDEster Del Duca
Ester Del Duca
DDDante Dahabreh
Dante Dahabreh
DODaniel Lozano Ojalvo
Daniel Lozano Ojalvo
BCBritta Carroll
Britta Carroll
EGEmma Guttman‐Yassky
Emma Guttman‐Yassky

23 September 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MKMadeline Kim
Madeline Kim
YRYael Renert-Yuval
Yael Renert-Yuval
PSPolina Stepensky
Polina Stepensky
EEEhud Even-Or
Ehud Even-Or
IZIrina Zaidman
Irina Zaidman
EGEmma Guttman-Yassky
Emma Guttman-Yassky

24 May 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
MHMaria Helm
Maria Helm
MSMaria Schmidt
Maria Schmidt
EDEster Del Duca
Ester Del Duca
YLYing Liu
Ying Liu
LMLena Sünke Mortensen
Lena Sünke Mortensen
RFRubén A. Ferrer
Rubén A. Ferrer
Skin-injury and several diseases elicit fibrosis and induce hair follicle (HF)-growth arrest and loss. Resulting alopecia and disfiguration represent a severe burden for patients both physically and psychologically. Reduction of pro-fibrotic factors such as DPP4 might be a strategy to tackle this issue. We demonstrate DPP4-overrepresentation in settings with HF-growth arrest (telogen), HF-loss and non-regenerative wound areas in mice skin and human scalp. Topical DPP4-inhibition (DPP4i) with FDA/EMA-approved Sitagliptin (Sit) on preclinical models of murine HF-activation/regeneration results in accelerated anagen-progress, while treatment of wounds with Sit results in reduced expression of fibrosis markers, increased induction of anagen around wounds, and HF-regeneration in the wound center. These effects are associated with higher expression of Wnt-target Lef1, known to be required for HF-anagen (HF-activation)/regeneration. Sit-treatment decreases pro-fibrotic signaling in the skin, induce a differentiation trajectory of HF-cells, and activate Wnt-targets related to HF-activation/growth but not those supporting fibrosis. Taken together, our study demonstrates a role for DPP4 in HF biology and shows how DPP4i, currently used as oral medication to treat diabetes, could be repurposed into a topical treatment agent to potentially reverse HF-loss in alopecia and after injury.

7 March 2026 in Allergy
Verified
Journal Article
Closed access
KYKazuhiko Yamamura
Kazuhiko Yamamura
DDDante Dahabreh
Dante Dahabreh
EDEster Del Duca
Ester Del Duca
DODaniel Lozano Ojalvo
Daniel Lozano Ojalvo
MKMadeline Kim
Madeline Kim
EGEmma Guttman‐Yassky
Emma Guttman‐Yassky